Speaker(s): 

Liping Li, MD, Resident, Geisinger - has nothing to disclose.

Sahrish Shah, MD, Resident, Geisinger - has nothing to disclose.

Moderator(s): 

Zachary Hoffer, MD, Staff Physician, Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Explain the diagnostic challenges in distinguishing Merkel cell carcinoma (MCC) from small cell lung carcinoma (SCLC) and how current immunohistochemical markers fall short, particularly in MCPyV-negative and keratin 20-negative MCC cases.
• Evaluate the clinical utility of POU4F3 as a novel immunohistochemical marker by examining its sensitivity, specificity, and effectiveness in detecting MCC, including single-cell metastases in sentinel lymph nodes.
• Explain the clinical rationale and methodology behind using low-dose platelet transfusions in actively bleeding cardiac surgery patients.
• Evaluate the effectiveness and safety of low-dose platelet transfusions based on clinical outcomes.

Disclosure of Relevant Financial Relationships without Commercial Interests:

The Planning Committee consisting of Zachary Hoffer, MD PhD have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure:  None.

This presentation/content is HIPAA compliant. 

Commercial Support for this Session:  None.